As of Tuesday, December 30, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 9.99%, which has investors questioning if this is right time to sell.

The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.

It’s the season for flu and illnesses, but one virus in particular, adenovirus, has spread rapidly throughout the country ...

Flu is rising rapidly across the U.S., driven by a new variant of the virus. The Centers for Disease Control and Prevention ...